Lymphocyte Immunophenotyping in Common Variable Immunodeficiency
Recruitment status was Recruiting
The purpose of this study is to discover if differences in the surface markers of B-cells (antibody producing cells of the immune system) in Common Variable Immune Deficiency (CVID) are related to CVID or its complications/treatment (e.g. bronchiectasis, granulomatous disease, immunoglobulin treatment).
The study hypothesis is that the altered B-cell surface markers are related to CVID, and not to the complications or treatment of CVID.
Common Variable Immunodeficiency
|Study Design:||Observational Model: Case Control
Time Perspective: Cross-Sectional
|Official Title:||Investigation of the Lymphocyte Surface Expression of Patients With Primary Immunodeficiency (Common Variable Immunodeficiency (CVID)), Compared to Controls|
- Percentage of B-cells of all lymphocytes [ Time Frame: 5 months ] [ Designated as safety issue: No ]Look at percentage of cells within the lymphocyte gate that express the B-cell marker CD19, and compare to healthy controls and non-healthy controls.
- Percentage of class switched memory B-cells as a percentage of B-cells [ Time Frame: 5 months ] [ Designated as safety issue: No ]Percentage of class-switched memory B-cells (expressing CD27 and CD19), that do not express IgM or IgD, as a percentage of B-cells. This is reduced in CVID and this will be compared between controls and the patients with CVID.
- Percentage expression of CD21 and CD38 [ Time Frame: 5 months ] [ Designated as safety issue: No ]Look for abnormalities in the CVID group and compare to control groups in the numeber of B-cells expressing low levels of CD21 (CD21 lo), and high CD38.
Biospecimen Retention: Samples With DNA
Blood serum samples kept for one year in secure laboratory.
|Study Start Date:||March 2010|
|Estimated Study Completion Date:||July 2011|
|Primary Completion Date:||June 2010 (Final data collection date for primary outcome measure)|
Patients with common variable immunodeficiency
CVID and granulomatous disease
Patients with CVID complicated with granulomatous inflammation
CVID and bronchiectasis
Patients with CVID complicated by bronchiectasis
Control on Immunoglobulin
Patients on immunoglobulin long-term who do not have an immunodeficiency
Controls with bronchiectasis not caused by a known immunodeficiency
Control with granulomatous disease
Control patients with Crohn's Disease as this is a disease that causes granulomatous inflammation.
Common Variable Immune Deficiency (CVID) is a syndrome containing a spectrum of disorders which results in weakened immunity and recurrent infections. The ESID (European Society for Immunodeficiencies) CVID definition includes patients with marked decrease of IgG (at least 2 standard deviations below the mean for age). Patients must also have disease onset at an age over 2 years, absent isohaemagglutinins and/or response to vaccines and other defined causes of hypogammaglobulinaemia must be excluded. The Euroclass system of classifying CVID is the result of a European multicentre trial attempting to develop a consensus of two existing classification schemes of B-cell immunophenotyping. In this paper it was shown that B-cell immunophenotype correlated with coincidence of clinical sequelae and it suggested implementing this to further classify CVID to give prognostic and therapeutic information. However, it has not yet been shown that these alterations in B-cell immunophenotype are the result of CVID itself and not caused by the treatment or complications of CVID (e.g. immunoglobulin replacement therapy, granulomatous disease, bronchiectasis). The aim of this study is to show that alterations in B-cell immunophenotype are caused by CVID itself and not by its complications or treatment. The study will therefore compare CVID patients to suitable control patients with granulomatous disease, bronchiectasis and on long-term immunoglobulin therapy. A control group of normal people will also be included to ensure the assay can detect normality and to show differences between normal people and patients with CVID.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01196702
|Contact: Philip Bright, MBBSemail@example.com|
|Contact: Hilary Bright, MBBSfirstname.lastname@example.org|
|Barts and the London NHS Trust||Recruiting|
|London, United Kingdom, E1 1BB|
|Contact: Gerry Leonard 02078827260 email@example.com|
|Principal Investigator: Hilary Longhurst, MBBS, PhD|
|Principal Investigator:||Hilary Longhurst, MBBS, PhD||Barts and the London NHS Trust|